NHP Site Licence Amendments in Canada: When You're Required to Notify Health Canada

Most natural health product companies treat their site licence like a fixed credential — something obtained once, filed away, and renewed each year without much thought. That approach works fine until you add a new activity, move equipment to a different building, or bring a Qualified Person on board mid-year. Then the paperwork catches up quickly.

Under the Natural Health Products Regulations (NHPR, SOR/2003-196), a site licence isn’t a blanket authorization to operate as an NHP company. It authorizes named activities at a named facility. Change either of those, and you’re almost certainly looking at a mandatory amendment filing — and if you make the operational change first and file afterward, you may have been operating outside your licence for months without realizing it.

Here’s what actually triggers an amendment, how the process works, and where companies consistently get tripped up.

What Your Site Licence Actually Authorizes (and What It Doesn’t)

Section 25(1) of the NHPR is specific: no person shall manufacture, package, label, or import a natural health product without holding a site licence that explicitly authorizes that activity. Distribution and storage arrangements can also require site-level authorization depending on your company’s contractual role in the supply chain.

The operative word is authorizes. Your licence doesn’t say “this company may generally work with natural health products.” It names this company, at this physical address, performing these listed activities. That level of specificity is deliberate — it’s what allows the Natural and Non-prescription Health Products Directorate (NNHPD) to know exactly what operations are happening at each licensed facility and design targeted GMP inspections accordingly.

The practical consequence of that specificity is one that catches growing companies off guard. If your site licence lists “packaging and labelling” and you start importing raw materials for a contract manufacturing client, the import activity isn’t covered. Even if you hold valid product licences (NPNs) for every finished product leaving your facility, the site-level activity of importing requires its own separate authorization. The NPN and the site licence answer different regulatory questions — what product, and who is doing what to it where.

What Changes Require a Mandatory Amendment Under the NHPR

Health Canada distinguishes between two tiers of amendment: changes that require pre-approval before you implement them, and changes you can make and then report. That distinction has real operational consequences. With a notification-only change, you file and proceed. With a pre-approval change, you wait for NNHPD confirmation before touching anything.

Changes that require pre-approval before implementation:

• Adding a new licensed activity — the most common trigger. Moving from a packaging-only licence to one that includes manufacturing, or adding import authorization to an existing licence, requires Health Canada to assess whether your facility and quality system support the expanded scope.
• Adding a new dosage form category — if your licence covers solid oral dosage forms and you want to begin producing topical liquids or semi-solids, that’s a material GMP scope change, not an administrative update.
• Relocating your facility — even moving to a larger space in the same building or to a unit next door. The address recorded on your site licence is specific; a new address requires a new site assessment.
• Adding a new building or annex — if manufacturing or storage moves to a physically separate structure, even on the same property, that structure needs to be included in your licence authorization.
• Changes to senior quality personnel — in many cases, changes to the person responsible for ensuring GMP compliance at the site require notification or pre-approval depending on the role and the scope of the change.

Changes that can typically be reported after the fact:

• Administrative corrections — legal company name changes following a corporate restructuring, mailing address corrections for NNHPD correspondence.
• Contact detail updates — phone numbers and email addresses used for regulatory communications.

The honest caveat here: Health Canada’s guidance doesn’t always draw a perfectly bright line between these two categories. When you’re uncertain, put your question to the NNHPD in writing through Health Canada’s inquiry system and document the response. A written determination from the Directorate carries real weight if the classification of a change ever becomes a question during a GMP inspection — and inspectors do ask.

How to File an NHP Site Licence Amendment with Health Canada

Site licence amendments are submitted through Health Canada’s Health Products and Food Branch electronic submission system. The NNHPD has transitioned most licensing submissions to the eSubmission portal, though the Directorate still accepts paper submissions in limited circumstances.

Here is what the process actually involves:

Step 1: Retrieve your current site licence documentation. Pull your existing site licence, confirm your licence number, and document exactly what is currently authorized. You need a clear baseline before you can articulate what’s changing.

Step 2: Complete the NHP Site Licence Application form. For an amendment, you populate only the sections that are changing, clearly indicating that this is a revision to an existing licence rather than a new application. Include your current site licence number prominently.

Step 3: Prepare supporting GMP documentation. This step is where many companies underestimate the work involved. For activity additions, NNHPD typically expects updated facility floor plans, an overview of how your quality management system covers the new activity, and any relevant equipment or process qualifications. Submitting a bare amendment form with no supporting documentation almost guarantees a request for information (RFI) that adds weeks to your timeline.

Step 4: Submit through the eSubmission portal and retain your confirmation. Keep your submission confirmation number and save all correspondence with NNHPD. If a Health Canada inspector asks whether a specific change has been authorized, your amendment approval letter is the evidence.

Step 5: Wait for pre-approval before implementing. For changes requiring pre-authorization, NNHPD review timelines typically run 30 to 90 business days, depending on submission volume and the complexity of what you’ve filed. Operationally, that window needs to be built into your planning. Don’t schedule a facility move or a contract start date assuming the amendment will be turned around in two weeks.

Step 6: Update your quality system documentation. The amended site licence is the starting point, not the finish line. Your site master file, quality manual, and any SOPs affected by the change need to reflect the updated authorized scope before you begin operations under the amendment. GMP inspectors routinely check whether internal documentation aligns with the current site licence.

What Operating Outside Your Site Licence Authorization Actually Means

Part 3 of the NHPR (sections 25 through 33) gives Health Canada real enforcement options when site licence obligations aren’t met. Under section 33, the NNHPD may suspend or cancel a site licence if the holder fails to comply with the conditions of the licence or the requirements of the Regulations. That’s not a hypothetical consequence — it’s the mechanism the Directorate uses when inspection findings reveal that a company’s actual operations don’t match what their licence authorizes.

The downstream risk is more serious than a suspended licence. An NHP manufactured, packaged, or imported under an activity that isn’t authorized on the site licence may be considered an unlicensed product under the Food and Drugs Act. Unlicensed NHPs are subject to seizure, and the company faces potential administrative monetary penalties.

In practice, this scenario comes up regularly with companies scaling quickly. A small operation starts with a packaging and labelling licence, lands a contract that requires raw material importation, begins importing, and doesn’t connect the activity to the site licence authorization. Eighteen months later, a Health Canada GMP inspector notes the discrepancy. By that point, the company has a “critical” or “major” non-compliance on their inspection report and a retroactive amendment situation that’s significantly more complicated than the proactive filing would have been.

The fix isn’t technically difficult. But it’s dramatically harder to work through after an inspection than before one.

Build Amendment Reviews into Your Change Control Process

The clearest preventive measure is structural: make site licence review a mandatory step in your change control SOP. Any significant operational change — new location, new activity, new dosage form, new QP, new external facility being brought under your quality umbrella — should trigger a documented review of whether the proposed change falls within your current site licence authorization.

If the answer is “yes, clearly,” document that determination and move forward. If the answer is “no” or “uncertain,” the amendment process starts before the change does. Build that sequence into your change control form so the decision isn’t left to individual judgment under schedule pressure.

Companies that handle this well treat the NNHPD as a resource rather than an obstacle. The Directorate’s pre-submission inquiry process exists precisely to help licence holders resolve ambiguous situations before they become inspection findings. Use it.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• GMP compliance resources for US supplement and pharmaceutical manufacturers — Qalitex Laboratories provides ISO 17025-accredited testing and GMP compliance support for North American manufacturers.
• EU cosmetic and health product regulatory guidance for European market entry — Care Europe covers EU 1223/2009, REACH, and market authorization pathways for health product companies entering the European market.